Dianthus Therapeutics, Inc. Common Stock
DNTH
$105.60
+10.75%
Dianthus Therapeutics is a clinical-stage biotechnology company focused on developing next-generation therapies for severe autoimmune diseases, with its lead candidate Claseprubart targeting the complement pathway. The company operates as a single-segment business and is led by experienced biotech and pharma executives, positioning it as a potential disruptor in the autoimmune space. The current investor narrative centers on the promise of Claseprubart as a best-in-class complement therapeutic, with recent news highlighting a major fund's $55 million bet on the stock amid a 350% rally and a competitor's clinical setback that could bolster the market opportunity. The stock has surged over 424% in the past year, driven by pipeline optimism and strong analyst support.…
DNTH
Dianthus Therapeutics, Inc. Common Stock
$105.60
Related headlines
DNTH 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Dianthus Therapeutics, Inc. Common Stock's 12-month outlook, with a consensus price target around $128.58 and implied upside of +21.8% versus the current price.
Average Target
$128.58
0 analysts
Implied Upside
+21.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$105 - $200
Analyst target range
DNTH is covered by 12 analysts, with a consensus recommendation of 'Strong Buy' (mean score 1.0). The average target price is $128.58, implying approximately +28.7% upside from the current price of $99.91. The distribution leans heavily bullish, with no hold or sell ratings. The target range spans from a low of $105.00 to a high of $200.00. The high target of $200 assumes successful clinical data and potential commercialization of Claseprubart, likely factoring in multiple expansion and peak sales estimates. The low target of $105 suggests a more conservative view, pricing in pipeline risks or slower adoption. The wide spread (95% from low to high) indicates high uncertainty, typical for clinical-stage biotechs. Recent analyst actions have been uniformly positive, with upgrades from Raymond James (Strong Buy) and reaffirmations from Wedbush, Baird, and others following the March 2026 data readout. The strong buy consensus and recent upgrades reflect confidence in the pipeline, but the wide target range underscores the binary nature of clinical-stage investing.
Drowning in data?
Find the real signal!
Bulls vs Bears: DNTH Investment Factors
DNTH presents a high-risk, high-reward investment case typical of clinical-stage biotechs. The bull case is supported by unanimous analyst Strong Buy ratings, a strong cash position, and a forward P/S ratio that appears reasonable relative to expected revenue growth. The bear case highlights extreme trailing valuation, lack of profitability, and binary clinical risk. The most important tension is whether Claseprubart's clinical data will meet the high expectations embedded in the stock price. If positive data continues, the stock could re-rate higher; if not, the downside could be severe. Currently, the bull case has stronger evidence given analyst support and recent momentum, but the risk of failure remains substantial.
Bullish
- Unanimous Strong Buy Consensus: All 12 analysts rate DNTH a Strong Buy with a mean score of 1.0, and the average target price of $128.58 implies +28.7% upside from the current $99.91. This reflects high conviction in the pipeline, especially after recent positive data readouts.
- Massive Forward Revenue Growth Expected: Analysts estimate FY2026 revenue of $658.6 million, a dramatic increase from the trailing twelve-month revenue of ~$1.3 million. The forward P/S ratio of 2.4x is below the biotech industry average of 10-15x, suggesting the stock is pricing in a revenue inflection that may still be undervalued relative to peers.
- Strong Balance Sheet with $627.8M Cash: The company has $627.8 million in cash and negligible debt (debt-to-equity of 0.003), providing a runway of over 4 years at the current cash burn rate of ~$130 million TTM free cash flow. This financial cushion reduces dilution risk and supports pipeline development.
- Competitor Setback Boosts Market Opportunity: Recent news of Sanofi's clinical trial setback in CIDP could strengthen the position of complement-targeting therapies like Claseprubart. This removes a potential competitor and expands the addressable market for DNTH's lead candidate.
Bearish
- Extreme Valuation on Trailing Metrics: The trailing P/S ratio of 765x is astronomically high compared to the biotech industry average of 10-15x. While forward P/S is lower, the current price already embeds aggressive expectations for pipeline success, leaving little room for disappointment.
- Pre-Commercial with No Profitability in Sight: DNTH is unprofitable with a net loss of $40.8 million in Q1 2026 and negative free cash flow of -$130.5 million TTM. Operating margin is -100.5%, and the company has no approved products, making it entirely dependent on clinical trial outcomes.
- Binary Clinical Risk of Pipeline Failure: As a clinical-stage biotech, DNTH's valuation hinges on the success of Claseprubart. Any negative data readout or regulatory delay could cause a severe stock decline, as seen with many biotech stocks that fail in late-stage trials.
- Revenue Decline and Erratic Trajectory: Q1 2026 revenue of $463,000 was down 60.2% year-over-year, and revenue is derived from license fees, not product sales. The lack of a consistent revenue stream makes it difficult to value the company on fundamentals.
DNTH Technical Analysis
DNTH is in a powerful sustained uptrend, with a 1-year price change of +424.7% and the stock currently trading at $99.91, which is 97.6% of its 52-week range (high $102.37, low $18.08). This positioning near the 52-week high indicates strong momentum and bullish sentiment, though it also suggests the stock may be overextended in the short term. The 1-year relative strength vs. SPY is +403.8%, confirming significant outperformance. Over the past 1 month, DNTH has gained 21.1%, while the 3-month change is +7.5%, showing that short-term momentum is accelerating relative to the intermediate term. The 1-month relative strength vs. SPY is +20.5%, indicating strong recent outperformance. This divergence—where 1-month momentum outpaces 3-month—could signal a renewed bullish push rather than a reversal, especially given the stock's ability to hold above $90 in recent weeks. The 52-week high of $102.37 serves as immediate resistance, while the 52-week low of $18.08 is far below and not a near-term support. More relevant support lies around $80, the June low. The beta of 0.089 is extremely low, suggesting the stock's price movements are largely uncorrelated with the broader market, which is unusual for a biotech and may reflect company-specific drivers dominating. A breakout above $102.37 would signal a continuation of the uptrend, while a breakdown below $80 could indicate a deeper correction.
Beta
0.09
0.09x market volatility
Max Drawdown
-20.2%
Largest decline past year
52-Week Range
$18-$106
Price range past year
Annual Return
+418.9%
Cumulative gain past year
| Period | DNTH Return | S&P 500 |
|---|---|---|
| 1m | +29.0% | +0.3% |
| 3m | +13.2% | +4.7% |
| 6m | +139.5% | +7.5% |
| 1y | +418.9% | +18.4% |
| ytd | +166.1% | +9.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
DNTH Fundamental Analysis
DNTH's revenue trajectory is highly erratic and minimal, with Q1 2026 revenue of $463,000, down 60.2% year-over-year from $1.163 million in Q1 2025. Revenue is derived from license fees, and the multi-quarter trend shows significant volatility: Q4 2025 revenue was $284,000, Q3 2025 was $396,000, and Q2 2025 was $193,000. The company is pre-commercial, and revenue is not a meaningful driver of value; instead, the investment case hinges on clinical pipeline progress. The company is unprofitable, with a net loss of $40.8 million in Q1 2026, compared to a net loss of $29.5 million in Q1 2025. Gross margin was 83.6% in Q1 2026, but operating margin was -100.5%, reflecting heavy R&D spending ($34.5 million in Q1 2026) and G&A costs ($12.5 million). Net margin was -88.2%, and the trailing twelve-month free cash flow was -$130.5 million. The company has a strong balance sheet with $627.8 million in cash at the end of Q1 2026, following a $739.4 million equity offering. Debt-to-equity is negligible at 0.003, and the current ratio is 29.3, indicating ample liquidity. However, the company is not yet generating positive free cash flow, and its ability to fund operations depends on its cash reserves and future financing. ROE is -32.9%, reflecting the net loss relative to shareholders' equity.
Quarterly Revenue
$463000.0B
2026-03
Revenue YoY Growth
-60.2%
YoY Comparison
Gross Margin
83.6%
Latest Quarter
Free Cash Flow
$-130485000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is DNTH Overvalued?
Since net income is negative (TTM net loss of $40.8 million), the P/E ratio is not meaningful, so we lead with the price-to-sales (P/S) ratio. The trailing P/S ratio is 765x, while the forward P/S (based on estimated revenue of $658.6 million) is approximately 2.4x, implying the market expects massive revenue growth from pipeline milestones or partnerships. The gap between trailing and forward P/S suggests aggressive growth expectations. Compared to the biotechnology industry average P/S of roughly 10-15x, DNTH's trailing P/S of 765x is astronomically high, but the forward P/S of 2.4x is actually below the industry average, reflecting the anticipated revenue inflection. The premium/discount is not directly comparable due to the pre-revenue stage. Historically, DNTH's P/S ratio has ranged from 20x (2022) to over 8,700x (Q1 2026), and the current trailing P/S of 765x is near the lower end of its recent range, suggesting the market is pricing in a significant revenue ramp. The price-to-book ratio of 3.16x is above the historical low of 0.28x (Q4 2023) but below the high of 3.36x (Q1 2026), indicating the stock is trading near the top of its book value multiple range, which could imply optimism about future profitability.
PE
-9.8x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-9.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: DNTH is pre-commercial with no approved products, generating minimal and declining revenue ($463,000 in Q1 2026, down 60.2% YoY). The company is deeply unprofitable, with a net loss of $40.8 million in Q1 2026 and negative free cash flow of -$130.5 million TTM. While the cash balance of $627.8 million provides a multi-year runway, the burn rate is high, and any delays in pipeline progress could necessitate dilutive financing. The operating margin of -100.5% underscores the heavy R&D spending ($34.5 million in Q1 2026) required to advance Claseprubart, with no guarantee of success.
Market & Competitive Risks: The stock trades at a trailing P/S of 765x, far above the biotech industry average of 10-15x, implying extreme growth expectations. If Claseprubart fails or faces regulatory hurdles, the valuation could collapse. The competitive landscape includes established therapies like Argenx's Vyvgart, though Sanofi's recent setback may reduce near-term competition. The beta of 0.089 indicates low market correlation, but the stock is highly sensitive to company-specific news, making it vulnerable to binary events. The short ratio of 6.36 suggests elevated short interest, reflecting bearish bets against the stock.
Worst-Case Scenario: If Claseprubart fails in clinical trials or receives a negative regulatory decision, the stock could fall to its 52-week low of $18.08, representing a potential loss of -81.9% from the current price of $99.91. This scenario would likely involve a complete reassessment of the pipeline value, with the stock trading closer to cash value per share (~$13 based on $627.8M cash and 48M shares). Historical max drawdown of -20.2% is mild, but a clinical failure could far exceed that.
